Company: TELO
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-023970
Chunk: 46

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Item 8
Chunk 46
---
), an ultra-rare genetic disorder characterized by premature aging and shortened lifespan.

●
On June 11, 2025, Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) announced new preclinical data demonstrating that its lead small molecule
candidate, Telomir-1, significantly improved neurological, behavioral, liver- and kidney-related outcomes in a clinically relevant animal
model of Wilson’s disease (ATP7B C271X -/- zebrafish).

●
On July 17, 2025, we reported new preclinical results evaluating the effects of its lead candidate, Telomir-1, in a murine xenograft
model using PC3 human prostate cancer cells. The data demonstrated that Telomir-1 reversed epigenetic silencing by DNA methylation of
the STAT1 gene, a tumor suppressor and immune response regulator, in a dose-dependent manner.

●
On July 18, 2025, we sold a total of 1,100,000 shares of its common stock, no par value, in block sales to institutional investors, at
an average price of $2.6045 per share (a premium to the prior day’s close), through its at-the-market equity offering facility.

●
On July 23, 2025, we reported new preclinical results showing that its lead compound, Telomir-1, restored mitochondrial function
without triggering oxidative stress or cell proliferation in human cells derived from a patient with Hutchinson-Gilford Progeria Syndrome
(HGPS).

14

Components
of Our Results of Operations

Research
and development expenses represent costs incurred to conduct research and development of our product candidate. We recognize all research
and development costs as they are incurred. Research and development expenses consist primarily of the following:

    ●
    contracted
    research and manufacturing;

    ●
    consulting
    arrangements; and

    ●
    other
    expenses incurred to advance the Company’s research and development activities.

Our
operating expenses have historically been the costs associated with our initial investment in pre-clinical research and development activities.
We expect research and development expenses to increase in the future as we advance Telomir-1 into and through clinical trials and pursue
regulatory approvals, which will require a significant investment in costs of clinical trials, regulatory support, and contract manufacturing.
In addition, we will evaluate opportunities to acquire or in-license additional product candidates and technologies, which may result
in higher research and development expenses